Lipella Pharmaceuticals Inc.
Performance History
| Key Stats | |
|---|---|
| Open | $1.14 |
| Prev. Close | $1.14 |
| EPS | -0.74 |
| Dividend | $0.00 |
| Next Earnings Date | Jun 30, 2023 |
| Dividend Yield % | - |
| Market Cap | $6.64M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 1.12 | 1.20 |
| 52 Week Range | 0.85 | 7.72 |
| Ratios | |
|---|---|
| P/B Ratio | 2.98 |
| Revenue | $210.99M |
| Operating M. % | -1,303.91% |
| Earnings | -$4.29M |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -397.79% |
| EPS | -0.74 |
Score Breakdown
All Score (47 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| LIPO | Market | |
|---|---|---|
| Value | 56 | 42 |
| Quality | 61 | 46 |
| Ownership | 7 | 39 |
| Growth | 13 | 44 |
| Dividends | - | 32 |
All Score (47 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Lipella Pharmaceuticals Inc. (LIPO)
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jonathan Kaufman M.B.A., Ph.D.
- Headquarters
- Pittsburgh
- Employees
- 5
Keep an eye on Lipella Pharmaceuticals Inc.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.